Sanofi (SNY) Set to Release Quarterly Earnings on Friday

Sanofi (NASDAQ:SNY) will likely be posting its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to announce earnings of $1.63 per share and revenue of $14.84 billion for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, October 30, 2026 at 8:30 AM ET.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The business had revenue of $13.36 billion during the quarter. During the same period last year, the firm posted $3.24 earnings per share. The company’s quarterly revenue was up 16.0% on a year-over-year basis. On average, analysts expect Sanofi to post $5.00 EPS for the current fiscal year and $5.19 EPS for the next fiscal year.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $42.24 on Thursday. The company has a market cap of $102.41 billion, a PE ratio of 22.12, a P/E/G ratio of 1.28 and a beta of 0.33. Sanofi has a fifty-two week low of $39.07 and a fifty-two week high of $52.68. The firm has a 50-day simple moving average of $42.28 and a 200 day simple moving average of $44.40. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SNY. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Thursday, October 1st. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, September 17th. Royal Bank Of Canada initiated coverage on Sanofi in a report on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Wall Street Zen downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Berenberg Bank restated a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $49.50.

About Sanofi

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.